Latex particle-enhanced turbidimetric immunoassay
Latex particle-enhanced turbidimetric immunoassay

Latex particle-enhanced turbidimetric immunoassay (LETIA) is commonly used to quantify serum protein in a homogenous system, which is accurate and stable. In LETIA, antibodies are covalently attached to polymer latex microspheres with antigen binding site exposed, and turbidimetric of reaction solution is changed when antibody-microsphere-antigen complex is formed. Besides, linear correlation between antigen concentration and absorbance at a specific range makes this assay applicable to quantify concentration of antigen.

LETIA provides a lot of advantages over other widely-used assays, such as enzyme-linked immunosorbent assay (ELISA), Radioimmunoassay (RIA) and gold-colloid immunochromatographic assay (GICA). Firstly, LETIA avoids the steps to incubate and wash repeatedly and is much more rapid than ELISA. Secondly, LETIA can be used in quantitative analysis and provides better sensitivity than GICA. Finally, LETIA is a non-radioactive method and provides better stability than RIA.

Nowadays, mock, amino- or carboxyl-modified microspheres are adopted in LETIA. These amino or carboxyl microspheres are covalently attached with antibodies, which enhances binding affinity with little effect on the 3D structure of antibodies, so sensitivity and specificity of this assay are enhanced. Besides, nanospheres that usually have a diameter at the range between atomic scale and macro-scale provide high surface-to-volume ratio, which speeds up the recruitment of substrate and enhances the stability of adsorption equilibrium, so application of nanospheres in LETIA facilitates immune reaction and improves quantification stability. In all, LETIA provide better sensitivity and stability than traditional turbidimetric immunoassay.

LETIA is a very promising technology, which can be widely used in various kind of inspection, such as some specific proteins or tumor makers. Lumigenex has applied these homogeneous and thermo-stable functionalized nanospheres to developing various in vitro diagnosis products, such as RBP, β2-MG, CYS-C, CRP and other quantification kits.

April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.